<span item_type="fundamental" item_id="71a20dbdc999d075cbb1f957cefbc4b4" counter_id="ST/US/RPRX" env="prod"></span><span item_type="announcement" item_id="645345444205892609" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 631 M.</p><p>EPS: As of FY2026 Q1, the actual value is USD 0.53.</p><p>EBIT: As of FY2026 Q1, the actual value is USD 657 M.</p><p></p><h4>Revenue and Receipts</h4><ul><li>Royalty Pharma plc’s Portfolio Receipts increased by 10% to $925 million for the first quarter of 2026, up from $839 million in the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li><li>Royalty Receipts grew 13% to $887 million in the first quarter of 2026, compared to $788 million in the first quarter of 2025, driven mainly by Tremfya, Voranigo, and Evrysdi, partially offset by a decline from Promacta due to U.S. generic competition.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li><li>Milestones and other contractual receipts were $38 million in the first quarter of 2026, a -25% change from $51 million in the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li><li>Total income and other revenues were $631 million for the first quarter of 2026, compared to $568 million for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li></ul><h4>Net Income</h4><ul><li>Consolidated net income was $468 million for the first quarter of 2026, an increase from $434 million for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li><li>Net income attributable to Royalty Pharma plc was $295 million for the first quarter of 2026, up from $239 million for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li></ul><h4>Operating Expenses and Income</h4><ul><li>Total operating expense, net was $68 million for the first quarter of 2026, compared to $34 million for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li><li>Operating income was $563 million for the first quarter of 2026, an increase from $534 million for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li><li>Payments for operating and professional costs were -$36 million for the first quarter of 2026, a decrease from -$102 million in the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li><li>Financial royalty asset impairment charges were $69 million in the first quarter of 2026, related to Tazverik.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li></ul><h4>Cash Flow</h4><ul><li>Net cash provided by operating activities was $718 million for the first quarter of 2026, an increase of 20% from $596 million in the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li><li>Net cash used in investing activities was -$478 million for the first quarter of 2026, compared to $504 million provided by investing activities in the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li><li>Net cash used in financing activities was -$273 million for the first quarter of 2026, compared to -$941 million in the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li></ul><h4>Non-GAAP Metrics</h4><ul><li>Adjusted EBITDA increased by 21% to $889 million in the first quarter of 2026, from $738 million in the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li><li>Portfolio Cash Flow increased by 18% to $722 million in the first quarter of 2026, from $611 million in the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li><li>Capital Deployment was -$528 million in the first quarter of 2026, compared to -$101 million in the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li></ul><h4>Balance Sheet and Other Metrics</h4><ul><li>Cash and cash equivalents stood at $586 million as of March 31, 2026, down from $619 million as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li><li>Total debt with principal value was $9.2 billion as of March 31, 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li><li>Weighted average Class A ordinary shares outstanding - diluted decreased by 4% to 557 million for the first quarter of 2026, from 578 million for the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li><li>Royalty Pharma plc repurchased approximately 1.1 million Class A ordinary shares for $50 million in the first quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li><li>A quarterly dividend of $0.235 per share was paid, totaling $136 million in dividends and distributions in the first quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li><li>The company acquired three royalties for $1.25 billion in announced value during the first quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li></ul><h4>Outlook / Guidance</h4><ul><li>Royalty Pharma plc raised its full year 2026 guidance for Portfolio Receipts to between $3,325 million and $3,450 million, representing an expected Royalty Receipts growth of 4% to 8%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li><li>Payments for operating and professional costs are anticipated to decrease as a percentage of Portfolio Receipts in 2026 compared to 2025, primarily due to the extinguishment of the management fee.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li><li>Total interest paid is projected to be approximately $350 million to $360 million for the full year 2026, assuming no additional debt financing.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm"></span></li></ul>

Royalty Pharma PLC - CL | 8-K: FY2026 Q1 Revenue: USD 631 M